When is SNOA's next earnings date?

Based on SEC filing cadence, Sonoma Pharmaceuticals Inc. (SNOA)'s next quarterly reporting window is estimated around Dec 29, 2026.

How much is SNOA stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for SNOA, spanning a range between $1 and $1.24.

Stock Ratings / Health Care / SNOA / earnings

TNON (30) INBS (27) NVNO (33) WOK (51) ⌘ Pro Terminal →

Sonoma Pharmaceuticals Inc. (SNOA) Next Earnings Date & Expected ±12.5% Move

$1.10 0.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.10

Sonoma Pharmaceuticals Inc. (SNOA) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $5.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SNOA Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SNOA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Sonoma Pharmaceuticals Inc. (NASDAQ: SNOA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $1.10 (0.00% 1D, market cap $5.3M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 7/20. Across 1016 tracked Health Care issuers, SNOA ranks #658 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SNOA compare to TNON and INBS in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), SNOA carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of 38.0%, and ROIC of -35.0%. By comparison, TNON (Tenon Medical Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $5.5M) and INBS (Intelligent Bio Solutions Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $5.8M). Among the 5-stock peer group, SNOA leads on earnings multiple (N/A) while SNOA leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SNOA?

▼

Per SNOA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-03-31, CIK 0001367083), Sonoma Pharmaceuticals Inc. generated $19.5M in revenue (+36.7% YoY), $3.2K in net income, and -$4.1M in free cash flow against $13.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.10 (-0.19%)🧬 Disciplined Float (+0.16% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-10.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SNOA)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (34/100 Composite)

🔍 WHY SNOA SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (38% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Insider Conviction & Share Dilution+7/20 pts (21% of score)

SEC Form 4 / 13F Thermometer: 35% Net Buy • Disciplined Float (+0.16% YoY Shares)

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$1.18-2.5% Next Q

Q2 (-2Q)

Grade E$1.15+0% Next Q

Q3 (-1Q)

Grade E$1.15-4.3% Next Q

Current

Grade E$1.10-8.7% Hist 90D α

Trajectory: D (42) → E (34)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SNOA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SNOA currently carries a cautious 34/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.23) and Max Pain ($1.16) forces dealer call-delta covering toward $4.17.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.16% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SNOA• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “SNOA Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”

YES 34%NO 66%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 29, 2026 (~56 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.14 Expected Swing

MODEL EARNINGS SETUP GAUGE

SNOA Quantitative Pre-Earnings Setup: 34/100

Trailing EPS: $4.25 • YoY Revenue Growth: 36.7%

Model Bullish Setup (34/100)Model Risk Weight (66/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2026-03-31	$19.5M	$3.2K	-$4.1M	38%
FY 2024	2025-03-31	$14.3M	$3.5K	-$168.0K	38.2%
FY 2023	2024-03-31	$12.7M	$4.8K	-$2.4M	38%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SNOA)

✓Walkthrough of SNOA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SNOA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -9.84%🛡️ HOLDING TREND SUPPORT

2026-11-03O $1.20H $1.20L $1.10C $1.10VOL 85.8K

RES: $1.51SUP: $1.07SMA50: $1.23SMA200: $1.68

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SNOA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SNOA Butterfly Map → + Track SNOA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +36.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SNOA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SNOA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SNOA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SNOA)

Health Care Rank #658 of 1016 ⚔️ TNON vs SNOA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SNOA vs. TNON, INBS, NVNO, WOK)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Sonoma Pharmaceuticals Inc. (SNOA) ranks #658 by composite RQD confidence (34/100, grade E) and #937 by equity capitalization ($5.3M). Within this direct 5-issuer industry benchmark cohort, SNOA leads on earnings valuation at N/A trailing P/E, while SNOA leads on capital efficiency and profitability with -35.0% ROIC and 38.0% gross margin. WOK currently holds the highest overall quantitative score in the immediate peer group at 51/100 (D) compared with SNOA at 34/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SNOA ACTIVE Sonoma Pharmaceuticals Inc.	E	34/100	—	38.0%	-35.0%	0.00%	$5.3M	Benchmark Subject
TNON Tenon Medical Inc.	E	30/100	—	59.8%	-35.0%	-5.85%	$5.5M	/tnon-vs-snoa →
INBS Intelligent Bio Solutions Inc.	E	27/100	—	40.8%	-35.0%	-5.68%	$5.8M	/inbs-vs-snoa →
NVNO enVVeno Medical Corporation	E	33/100	—	—	-35.0%	+2.08%	$4.7M	/nvno-vs-snoa →
WOK WORK Medical Technology Group LTD (Class A)	D	51/100	—	—	—	0.00%	$4.5M	/wok-vs-snoa →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2026-03-31 • CIK 0001367083

In its most recent audited fiscal period (FY2025, filed 2026-03-31), Sonoma Pharmaceuticals Inc. (SNOA) reported GAAP revenue of $19.5M (+36.7% vs. FY2024 revenue of $14.3M , and +53.3% cumulative change since FY2023) , GAAP net income of $3.2K, operating cash flow of -$3.9M, and free cash flow of -$4.1M (-2355.4% YoY). On the balance sheet, SNOA closed FY2025 with $13.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2026-03-31	$19.5M	$3.2K	-$3.9M	-$4.1M	$13.6M	—
FY2024 (FY)	2025-03-31	$14.3M	$3.5K	-$88.0K	-$168.0K	$13.7M	—
FY2023 (FY)	2024-03-31	$12.7M	$4.8K	-$2.4M	-$2.4M	—	—

3. SNOA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SNOA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does SNOA compare to TNON and INBS in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for SNOA?

Where is SNOA trading relative to its 50-day, 200-day, and 52-week technical levels?

SNOA last traded at $1.10 (0.00% on volume of 42,243 shares), positioning the stock -10.57% below its 50-day simple moving average ($1.23) and -34.52% below its 200-day simple moving average ($1.68). Across its 52-week range of $0.85 to $3.97, SNOA sits at the 8.0% percentile with a 14-day RSI of 42.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.24).

Direct Sub-Reports: SNOA RQD Cockpit SNOA 12M Forecast SNOA Earnings & Move SNOA Dividends & DRIP SNOA Insiders & 13F SNOA Whale Options SNOA Profit Sankey SNOA News & Why

ROARABLE RATING BRIEF • RQD 34/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

SNOA — Sonoma Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:52:59Z

1. Roarable Rating Brief: What This Means to a Prospective Investor

SNOA scores 36 out of a possible 100, earning a letter grade of D- and the verdict label "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:

Fundamental Cash Engine: 5 / 20. The rating cites ROIC of -35% and an FCF yield of 0%. For a prospective investor, this pillar signals that the business is not currently generating returns on invested capital or free cash flow to shareholders, which removes the most common source of intrinsic support for an equity.
Whale / 13F Flow: 5 / 20. The rating references institutional accumulation and options positioning. The score is low, indicating weak large-holder conviction in the source data.
Insider Conviction: 7 / 20. The rating references SEC Form 4 and Congressional PTR cluster flow. The score is low, suggesting limited insider-driven confidence signals.
Macro Regime Fit: 6 / 20. The rating cites a beta of 1.0 and sector sensitivity. The score is below midpoint, meaning the stock's macro positioning offers limited cushion.
Forensic Balance Sheet: 13 / 20. The rating cites an Altman Z of 2.5, a Piotroski F of 4/9, and a Debt/Equity of 0.5. This is the strongest pillar, but it still reflects a middling financial-health profile rather than a robust one.

Taken together, the pillars describe a company with weak cash generation, thin institutional and insider conviction, and a balance sheet that is the relative bright spot. Valuation tradeoffs are significant: with a stock price of 1.2 and a market capitalization of $5.7M, the equity is small and volatile relative to its 52-week range of $0.85 - $4.01. Investors weighing this profile should note that the rating's own framing is a Sell verdict, and the factors driving it are structural (negative ROIC, zero FCF yield) rather than short-term.

2. Business Model, Unit Margins & SEC Financial Trajectory

Sonoma Pharmaceuticals Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Medical/Dental Instruments industry. The market capitalization is $0.0B. — The specific products, customer base, and revenue model are not described in the provided sources.

Revenue rose from $12.7M in FY 2023 to $19.5M in FY 2025, while operating income remained negative in each reported period, ending at -$2.5M in FY 2025. Net income is reported as — across all three periods. Gross margin is 38%, operating margin is -12.6%, and net margin is 0%, per the market data; ROIC is -35%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 4/9, . Cash declined from $5.2M in FY 2024 to $2.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case: Revenue grew from $12.7M in FY 2023 to $19.5M in FY 2025 and the forensic balance sheet pillar scored 13 of 20, the strongest in the rating. With Fundamental Cash Engine at 5/20 (ROIC -35.0%, FCF yield —) and Institutional Whale Flow at 3/20, sustained execution supports upside toward the top of the $0.85 – $3.97 52-week range.
🐻 Primary Bear Case: ROIC of -35%, a 0% FCF yield, and operating losses in every reported period leave the cash engine unproven while cash fell to $2.6M. Investors must weigh current valuation against -12.6% operating margins and a 1.00 macro beta if sector demand softens.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Medical/Dental Instruments (Health Care), SNOA carries a macro regime beta of 1.00 and gross margin of 38.0%.

Key Question #1: What is the debt position and cash runway, given that debt is listed as N/A and cash declined to $2.6M?
Key Question #2: Does the Kane Biotech Canadian distribution agreement involve SNOA, and what revenue or margin impact is expected?
Key Question #3: What drove the Q2 2026 narrow EPS miss, and what is the reported EPS figure?

SNOA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Sonoma Pharmaceuticals Inc. (SNOA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SNOA Debate Forum (3) ↓

🟡 MARKET WIRE TradingKey • 19h ago

Most Active Stocks Today: U.S. Market

TradingKey report covering Sonoma Pharmaceuticals Inc. (SNOA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST https://www.dars.gov.et/ • 22h ago

Sonoma Pharmaceuticals Q2 2026 Earnings: Narrow EPS Miss Keeps Shares Under Pressure - Dividend Growth Analysis

https://www.dars.gov.et/ report covering Sonoma Pharmaceuticals Inc. (SNOA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingKey • 1d ago

Unusual Volume Stocks & Volume Spikes Today

TradingKey report covering Sonoma Pharmaceuticals Inc. (SNOA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Mugglehead Investment Magazine • 1d ago

Kane Biotech signs Canadian distribution agreement for revyve wound care

Mugglehead Investment Magazine report covering Sonoma Pharmaceuticals Inc. (SNOA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingKey • 1d ago

Complete U.S. Stocks List: Prices, Performance and Key Data

TradingKey report covering Sonoma Pharmaceuticals Inc. (SNOA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingKey • 1d ago

Top U.S. Stock Losers: Biggest Price Declines

TradingKey report covering Sonoma Pharmaceuticals Inc. (SNOA) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SNOA Bull vs. Bear Conversation Board — What's Your Call at $1.10?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SNOA 🐻 33% BEARISH CONVICTION

MI MidwestValue Fundamental Long-Only 🐂 BULLISH 🎯 Target: $1.40 (+27.3%)

📌 Pinned Debate

Revenue grew from $12.7M in FY 2023 to $19.5M in FY 2025 and the forensic balance sheet pillar scored 13 of 20, the strongest in the ra

Revenue grew from $12.7M in FY 2023 to $19.5M in FY 2025 and the forensic balance sheet pillar scored 13 of 20, the strongest in the rating.. When you look under the hood at SNOA, Fundamental Cash Engine is 5/20 with 38.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (3/20) has been quietly accumulating below $3.97. My 12M target is $1.40.

RetailWhale_TX 🐂 BULL

Both sides have a point here — SNOA's 13/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

SK SkepticalCFA Fundamental Contrarian 🐻 BEARISH 🎯 Target: $0.95 (-13.6%)

Spot @ $1.10

ROIC of -35%, a 0% FCF yield, and operating losses in every reported period leave the cash engine unproven while cash fell to $2.6M.

ROIC of -35%, a 0% FCF yield, and operating losses in every reported period leave the cash engine unproven while cash fell to $2.6M.. Look at the math on SNOA: paying current EV/EBITDA multiples for -35.0% ROIC and -12.6% operating margins leaves zero margin of safety if Medical/Dental Instruments demand softens. I'd wait for a retest of $0.97 before getting long.